Ciliary body metastasis masquerading as scleritis.

of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60–76. 10 Mousa AR, Marafie AA, Rifai KM, et al. Behçet’s disease in Kuwait, Arabia. A report of 29 cases and a review. Scand J Rheumatol 1986;15:310–32. 11 Atmaca LS. Fundus changes associated with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 1989;227:340–4. 12 Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004;138:373–80. 13 Nussenblatt RB. Uveitis in Behçet’s disease. Int Rev Immunol 1997;14:67–79. 14 Sakamoto M, Akazawa K, Nishioka Y, et al. Prognostic factors of vision in patients with Behçet’s disease Ophthalmology 1995;102:317–21. 15 Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factor of poor visual outcome in Behçet’s disease with ocular involvement Graefes Arch Clin Exp Ophthalmol 2005;243:1147–52. 16 Pivetti-Pezzi P, Accorinti M, La Cava M, et al. Endogenous uveitis: an analysis of 1,417 cases. Ophthalmologica 1996;210:234–8. 17 Mizushima Y. Recent research into Behçet’s disease in Japan. Int J Tissue React 1988;10:59–65. 18 ISG for Behçets disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–80. 19 O’Duffy J. Criteres proposes pour le diagnostic de la maladie de Behçet’s et notes therapeutiques. Rev Med 1974;36:2371–9. 20 Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335–9. 21 Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 2004;31:1362–8. 22 Okada AA. Behçet’s disease: general concepts and recent advances. Curr Opin Ophthalmol 2006;17:551–6.